Bausch Health Companies Inc: Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference

Nine Poster Presentations Include New Analyses of SILIQ® and JUBLIA®LAVAL, QC / ACCESSWIRE / November 1, 2022 / - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its dermatology

Related Keywords

Canada ,United States ,Canadian ,Spreadability Kircik ,Kevin Wiggins ,Onychomycosis Lipner ,Richard Lajoie ,Las Vegas ,Christina Cheng ,Bausch Health Companies Inc ,Linkedin ,Twitter ,Bausch Health Investor Contact ,Lomb Corporation ,Exchange Commission ,Bausch Health Media Contact ,Bausch Health Companies Incview ,Bausch Health ,Nine Poster Presentations Include New Analyses ,Health Companies ,Ortho Dermatologics ,Dermatology Conference ,Topical Solution ,Ortho Dermatologic ,Therapy With Efinaconazole ,Toenail Onychomycosis ,Provides Rapid Onset ,Therapeutic Response ,Patients With Moderate To Severe Psoriasis ,Skin Clearance Achieved ,Moderate To Severe Psoriasis Through ,Truncal Acne ,Combination Halobetasol Propionate ,Tazarotene Lotion ,Plaque Psoriasis ,Patients With Affected Body Surface Area ,Poor Quality ,Topical Vehicle Design ,Fixed Combination Halobetasol Propionate ,Investigational Drug ,Fixed Dose Clindamycin ,Benzoyl Peroxide ,Moderate To Severe Acne ,Randomized Phase ,First Triple Combination Drug ,Safety Information ,Prescribing Information ,Important Safety Information ,Boxed Warning ,Canadian Securities Administrators ,Health Investor Contact ,Health Media Contact ,Bausch ,Health ,Companies ,Ortho ,Ermatologics ,Present ,Data ,022 ,Innovations ,Ermatology ,Conference ,